HK1121688A1 - Glucagon analogs exhibiting physiological solubility and stability - Google Patents

Glucagon analogs exhibiting physiological solubility and stability

Info

Publication number: HK1121688A1
Authority: HK; Hong Kong
Prior art keywords: stability; glucagon analogs; analogs exhibiting; exhibiting physiological; physiological solubility
Prior art date: 2005-11-07

Application number

HK09101716.2A

Other languages

English (en)

Chinese (zh)

Inventor

Richard D Dimarchi

David L Smiley

Original Assignee

Univ Indiana Res & Tech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-07

Filing date

2009-02-24

Publication date

2009-04-30

2009-02-24 Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp

2009-04-30 Publication of HK1121688A1 publication Critical patent/HK1121688A1/xx

Links

230000001747 exhibiting effect Effects 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

HK09101716.2A 2005-11-07 2009-02-24 Glucagon analogs exhibiting physiological solubility and stability HK1121688A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73430705P	2005-11-07	2005-11-07
PCT/US2006/043334 WO2007056362A2 (fr)	2005-11-07	2006-11-06	Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees

Publications (1)

Publication Number	Publication Date
HK1121688A1 true HK1121688A1 (en)	2009-04-30

Family

ID=38023925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK09101716.2A HK1121688A1 (en)	2005-11-07	2009-02-24	Glucagon analogs exhibiting physiological solubility and stability

Country Status (7)

Country	Link
US (2)	US8338368B2 (fr)
EP (2)	EP1959986B1 (fr)
CN (1)	CN101534846B (fr)
CA (2)	CA2628241C (fr)
ES (2)	ES2572952T3 (fr)
HK (1)	HK1121688A1 (fr)
WO (1)	WO2007056362A2 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL205971B1 (pl)	2001-09-24	2010-06-30	Imp Innovations Ltd	Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
AU2007221366B2 (en) *	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
ES2628063T3 (es) *	2007-01-05	2017-08-01	Indiana University Research And Technology Corporation	Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
CA2677932A1 (fr)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Co-agonistes des recepteurs du glucagon/glp-1
US8980830B2 (en) *	2007-10-30	2015-03-17	Indiana University Research And Technology Corporation	Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (fr) *	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Antagonistes du glucagon
CA2713348C (fr) *	2008-01-30	2018-10-09	Indiana University Research And Technology Corporation	Promedicaments peptidiques a base d'esters
MX2010013454A (es)	2008-06-17	2011-01-21	Tion Indiana University Res And Technology Corpora	Co-agonistas de receptor de glucagon/glp-1.
HUE028072T2 (en) *	2008-06-17	2016-11-28	Univ Indiana Res & Tech Corp	GIP-based agonists for the treatment of metabolic disease and obesity
US8450270B2 (en) *	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
JP5635529B2 (ja) *	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
NZ593813A (en) *	2008-12-15	2013-02-22	Zealand Pharma As	Glucagon analogues
BRPI0823379A2 (pt)	2008-12-15	2015-07-14	Zealand Pharma As	Análogos de glucagon
ES2477880T3 (es)	2008-12-15	2014-07-18	Zealand Pharma A/S	Análogos del glucagón
KR20110110174A (ko)	2008-12-19	2011-10-06	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
IN2012DN00377A (fr)	2009-06-16	2015-08-21	Univ Indiana Res & Tech Corp
RS53987B1 (en)	2009-07-13	2015-10-30	Zealand Pharma A/S	ANALYSIS OF ACYLATED GLUCAGON
WO2011075393A2 (fr)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Co-agonistes du récepteur du glucagon/glp-i
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JP2013518115A (ja)	2010-01-27	2013-05-20	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーション	代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
MX336412B (es)	2010-03-26	2016-01-19	Novo Nordisk As	Nuevos analogos de glucagon.
US20130053310A1 (en)	2010-03-26	2013-02-28	Novo Nordisk A/S	Novel glucagon analogues
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
ES2661228T3 (es)	2010-05-13	2018-03-28	Indiana University Research And Technology Corporation	Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
KR20130102470A (ko)	2010-06-24	2013-09-17	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
NZ604208A (en)	2010-06-24	2014-10-31	Zealand Pharma As	Glucagon analogues
JP5894174B2 (ja)	2010-11-03	2016-03-23	アレコーリミテッド	グルカゴンを含む新規組成物
KR20130132931A (ko)	2010-12-22	2013-12-05	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	Gip 수용체 활성을 나타내는 글루카곤 유사체들
CN103596583B (zh)	2011-03-28	2016-07-27	诺沃—诺迪斯克有限公司	新型胰高血糖素类似物
US8729017B2 (en)	2011-06-22	2014-05-20	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
LT2723367T (lt)	2011-06-22	2017-08-25	Indiana University Research And Technology Corporation	Bendri gliukagono/glp-1 receptoriaus agonistai
EP2729493B1 (fr)	2011-07-04	2020-06-10	IP2IPO Innovations Limited	Nouveaux composés et leurs effets sur le comportement alimentaire
IN2014CN02448A (fr)	2011-09-23	2015-06-19	Novo Nordisk As
KR20140097151A (ko)	2011-11-17	2014-08-06	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
WO2013164483A1 (fr)	2012-05-03	2013-11-07	Zealand Pharma A/S	Composés agonistes doubles du gip-glp-1 et méthodes
TWI599575B (zh)	2012-06-21	2017-09-21	印第安納大學科技研究公司	表現ｇｉｐ受體活性之胰高血糖素類似物
UA117103C2 (uk) *	2012-07-23	2018-06-25	Зіленд Фарма А/С	Сполука, яка має активність агоніста глюкагону
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
GB2505941A (en) *	2012-09-17	2014-03-19	Imp Innovations Ltd	Peptide analogues of glucagon for the treatment of obesity and diabetes
WO2014041375A1 (fr)	2012-09-17	2014-03-20	Imperial Innovations Limited	Analogues peptidiques du glucagon et du glp1
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA031428B1 (ru)	2012-12-21	2018-12-28	Санофи	Функционализированные производные эксендина-4
RU2678134C2 (ru)	2013-03-14	2019-01-23	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Конъюгаты инсулин-инкретин
WO2014170496A1 (fr)	2013-04-18	2014-10-23	Novo Nordisk A/S	Co-agonistes stables du récepteur du glucagon/glp -1 à action retardée et à usage médical
CN103333238A (zh) *	2013-06-18	2013-10-02	华东师范大学	一种mPEG-MAL-aGLP-1复合物
WO2014205617A1 (fr) *	2013-06-24	2014-12-31	Shandong University	Peptide marqué au lanthanide et utilisation de celui-ci
AU2014336098B2 (en)	2013-10-17	2018-05-10	Boehringer Ingelheim International Gmbh	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
WO2015067715A2 (fr)	2013-11-06	2015-05-14	Zealand Pharma A/S	Composés agonistes doubles de gip et glp-1 et procédés associés
EP3080150B1 (fr)	2013-12-13	2018-08-01	Sanofi	Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
EP3080152A1 (fr)	2013-12-13	2016-10-19	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
KR20160114082A (ko) *	2014-02-18	2016-10-04	노보 노르디스크 에이/에스	안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
EP3151852A1 (fr)	2014-06-04	2017-04-12	Novo Nordisk A/S	Co-agonistes de récepteur du glucagon/glp-1 à usage médical
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
ES2822994T3 (es)	2014-09-24	2021-05-05	Univ Indiana Res & Tech Corp	Conjugados de incretina-insulina
PE20180158A1 (es)	2014-10-24	2018-01-18	Merck Sharp & Dohme	Coagonistas de los receptores de glucagon y de glp-1
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
US10046058B2 (en)	2014-12-02	2018-08-14	Rezolute, Inc.	Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US10336802B2 (en)	2015-04-16	2019-07-02	Zealand Pharma A/S	Acylated glucagon analogue
BR112017023145A2 (pt)	2015-06-04	2018-07-10	Antriabio Inc	Método para produzir um conjugado de proteína- peg
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP3310373A4 (fr)	2015-06-22	2019-02-13	University of Utah Research Foundation	Agrafage de peptides à base de thiol-ène et utilisations associées
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106938050B (zh) *	2015-12-29	2021-08-24	派格生物医药(苏州)股份有限公司	包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
GB201611077D0 (en)	2016-06-24	2016-08-10	Arecor Ltd	Novel composition
WO2018017485A1 (fr)	2016-07-17	2018-01-25	University Of Utah Research Foundation	Agrafage de peptides à base de thiol-yne et utilisations associées
TW201832783A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
US10889627B2 (en) *	2017-06-29	2021-01-12	Ureka Sarl	Pro-drug peptide with improved pharmaceutical properties
CN109836488B (zh) *	2017-11-24	2022-08-23	浙江道尔生物科技有限公司	一种治疗代谢疾病的胰高血糖素类似物
JP2018090636A (ja) *	2018-03-15	2018-06-14	インペリアル・イノベイションズ・リミテッド	新規化合物及び摂食行動に対するそれらの効果
US20220153803A1 (en) *	2019-03-15	2022-05-19	Purdue Research Foundation	Modified glucagon molecues and formulations with oxidation resistance and methods and kits of employing the same
CN114853908B (zh)	2019-05-16	2024-06-07	浙江道尔生物科技有限公司	一种治疗代谢疾病的融合蛋白
CN110845601B (zh) *	2019-10-12	2021-01-19	广东药科大学	不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
WO2022232168A1 (fr)	2021-04-27	2022-11-03	Aardvark Therapeutics, Inc.	Combinaison d'un agoniste des récepteurs de l'amertume et d'un composé de signalisation intestinale
GB202109087D0 (en)	2021-06-24	2021-08-11	Norwegian Univ Sci & Tech Ntnu	Therapeutic methods and devices
CN115634285A (zh) *	2021-07-20	2023-01-24	派格生物医药(苏州)股份有限公司	多肽缀合物在制备治疗糖代谢相关疾病的药物中的应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275152A (en) *	1977-02-03	1981-06-23	Eastman Kodak Company	Hydrolysis of protein-bound cholesterol esters
PT83613B (en)	1985-10-28	1988-11-21	Lilly Co Eli	Process for the selective chemical removal of a protein amino-terminal residue
NZ232562A (en)	1989-02-17	1992-10-28	Coselco Mimotopes Pty Ltd	Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de)	1990-01-24	1998-07-30	Douglas I. Woodside Calif. Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
CA2024855C (fr)	1990-09-07	1997-12-09	Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee	Procede et intermediaires pour la production du glucagon
JPH04145099A (ja)	1990-10-05	1992-05-19	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) *	1991-01-17	1996-04-23	Zymogenetics, Inc.	Glucagon antagonists
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) *	1993-12-29	1996-01-02	The Rockefeller University	Glucagon analogs with serine replacements
GB9410469D0 (en) *	1994-05-25	1994-07-13	Erba Farmitalia	Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
EP0879279A4 (fr)	1996-02-06	2000-07-12	Lilly Co Eli	Therapie des diabetes
CA2257119A1 (fr)	1996-06-05	1997-12-11	Boehringer Mannheim Gmbh	Analogues exendine, procedes permettant de les preparer et medicaments les contenant
WO1998011126A1 (fr)	1996-09-09	1998-03-19	Zealand Pharmaceuticals A/S	Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998024464A1 (fr)	1996-12-03	1998-06-11	Trustees Of Boston University	Antagonistes specifiques du polypeptide glucodependant insulinotrope (gip)
JP4394279B2 (ja)	1998-03-09	2010-01-06	ジーランドファーマアクティーゼルスカブ	酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) *	1998-09-02	2003-12-25	Renuka Pillutla	Isulin and IGF-1 receptor agonists and antagonists
AU6294899A (en)	1998-10-07	2000-04-26	Medical College Of Georgia Research Institute, Inc.	Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
EP1137667B1 (fr)	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues du glp-1
JP2002534512A (ja)	1999-01-15	2002-10-15	ノボノルディスクアクティーゼルスカブ	非ペプチドｇｌｐ−１アゴニスト
WO2000058360A2 (fr)	1999-03-29	2000-10-05	Uutech Limited	Peptide
GB0404124D0 (en)	2004-02-25	2004-03-31	Univ Ulster	Antagonists of GIP
US6458493B2 (en) *	1999-06-04	2002-10-01	International Business Machines Corporation	Method to control nested to isolated line printing
AU2001257278A1 (en)	2000-04-27	2001-11-07	Bionebraska, Inc.	Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
EP1290019A2 (fr) *	2000-06-14	2003-03-12	Cytovax Biotechnologies Inc.	Utilisation d'un echafaudage structural a superhelice afin de generer des peptides specifiques de structure
KR100847615B1 (ko)	2000-06-16	2008-07-21	일라이 릴리 앤드 캄파니	글루카곤-유사 펩티드-1 유사체
JP2004509079A (ja)	2000-08-02	2004-03-25	セラテクノロジーズ・インコーポレーテッド	効力が増大した修飾生体ペプチド
US20020045572A1 (en)	2000-08-15	2002-04-18	Cpd, Llc	Method of treating the syndrome of type 2 diabetes in humans
US6846831B2 (en)	2000-08-15	2005-01-25	Cpd, Llc	Method of treating the syndrome of lipodystrophy
US6262062B1 (en)	2000-08-15	2001-07-17	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en)	2000-08-15	2003-03-04	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002026265A2 (fr) *	2000-09-29	2002-04-04	Schering Corporation	Interleukine 10 pegylee
AU2002228608A1 (en)	2000-12-13	2002-06-24	Eli Lilly And Company	Amidated glucagon-like peptide-1
DE60228972D1 (de)	2001-07-31	2008-10-30	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
JP2005509409A (ja) *	2001-08-08	2005-04-14	ジェンザイム・コーポレーション	糖尿病および他の血糖疾患の治療方法
US7238663B2 (en) *	2001-08-28	2007-07-03	Eli Lilly And Company	Pre-mixes of GLP-1 and basal insulin
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AR036711A1 (es) *	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7041646B2 (en)	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CN1630709A (zh) *	2001-10-18	2005-06-22	百时美施贵宝公司	人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
EP1448222A4 (fr)	2001-10-19	2006-05-17	Lilly Co Eli	Melanges biphasiques de glp-1 et d'insuline
WO2003059378A2 (fr) *	2001-12-29	2003-07-24	Novo Nordisk A/S	Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
AR038102A1 (es)	2002-01-08	2004-12-29	Lilly Co Eli	Analogos extendidos de peptido 1 de tipo glucagon
US20030232761A1 (en)	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003239478A1 (en)	2002-06-04	2003-12-22	Eli Lilly And Company	Modified glucagon-like peptide-1 analogs
AU2003237933A1 (en)	2002-06-11	2003-12-22	Cellartis Ab	Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
EP1526864A4 (fr)	2002-06-15	2006-11-08	Enteromed Inc	Prevention et traitement d'une steatose hepatique non alcoolique (nafld), par antagonisme du recepteur du polypeptide insulinotropique gluco-dependant (gip)
JP2006501820A (ja) *	2002-09-06	2006-01-19	バイエル・フアーマシユーチカルズ・コーポレーシヨン	修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
US7192922B2 (en) *	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
JP2006514990A (ja) *	2002-12-27	2006-05-18	ディオベックス，インコーポレイテッド	インスリン誘発性低血糖の予防および制御のための組成物および方法
US20050059605A1 (en)	2003-01-31	2005-03-17	Krishna Peri	Chemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (fr)	2003-03-04	2004-09-16	Biorexis Pharmaceutical Corporation	Proteines protegees contre la dipeptidylpeptidase
PL1605897T3 (pl)	2003-03-19	2012-12-31	Lilly Co Eli	Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
AU2004228793B2 (en) *	2003-04-08	2009-10-08	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
AU2004240630B2 (en)	2003-05-15	2010-10-07	Trustees Of Tufts College	Stable analogs of peptide and polypeptide therapeutics
WO2004105790A1 (fr)	2003-06-03	2004-12-09	Novo Nordisk A/S	Compositions peptidiques pharmaceutiques stabilisees
WO2004105781A2 (fr)	2003-06-03	2004-12-09	Novo Nordisk A/S	Compositions pharmaceutiques peptidiques stabilisees
CN101974090B (zh) *	2003-06-12	2015-06-17	伊莱利利公司	Glp-1类似物融合蛋白质
WO2004111078A2 (fr) *	2003-06-18	2004-12-23	Theratechnologies Inc.	Composes qui modulent la reponse du glucagon et utilisations associees
SI2932981T1 (sl) *	2003-09-19	2021-11-30	Novo Nordisk A/S	Albumin-vezavni derivati GLP-1
US7364875B2 (en) *	2003-10-30	2008-04-29	Cresent Innovations, Inc.	Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
DE602004026113D1 (de) *	2003-12-18	2010-04-29	Novo Nordisk As	Glp-1-verbindungen
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en)	2004-10-19	2008-10-28	Nitto Denko Corporation	Transepithelial delivery of peptides with incretin hormone activities
EA011653B1 (ru)	2005-02-11	2009-04-28	Амилин Фармасьютикалз, Инк.	Аналоги и гибридные полипептиды gip с избираемыми свойствами
WO2007022123A2 (fr)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides presentant des proprietes selectionnables
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
US20090062192A1 (en) *	2005-03-18	2009-03-05	Novo Nordisk A/S	Dimeric Peptide Agonists of the Glp-1 Receptor
WO2006121904A1 (fr)	2005-05-06	2006-11-16	Bayer Pharmaceuticals Corporation	Agonistes du recepteur du polypeptide insulinotropique gluco-dependant (gip) et procedes pharmacologiques d'utilisation associes
PT1881850E (pt)	2005-05-13	2010-11-26	Lilly Co Eli	Compostos peguilados de glp-1
DK1891105T3 (da)	2005-06-13	2012-07-16	Imp Innovations Ltd	Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
EP1937716A2 (fr)	2005-09-08	2008-07-02	Uutech Limited	Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement
US20090170762A1 (en)	2005-09-08	2009-07-02	Uutech Limited	Treatment of Diabetes Related Obesity
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
AU2007221366B2 (en)	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
ES2397659T3 (es) *	2006-03-15	2013-03-08	Novo Nordisk A/S	Mezclas de amilina e insulina
WO2007109354A2 (fr)	2006-03-21	2007-09-27	Amylin Pharmaceuticals, Inc.	Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
EP2574624A1 (fr)	2006-04-20	2013-04-03	Amgen Inc.	Composés GLP-1
WO2008022015A2 (fr)	2006-08-11	2008-02-21	Trustees Of Tufts College	Analogues rétro-inverso de l'incrétine, et procédés pour leur utilisation
EP2057188B1 (fr)	2006-08-17	2013-07-31	Amylin Pharmaceuticals, LLC	Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
EP2057189B1 (fr)	2006-08-25	2013-03-06	Novo Nordisk A/S	Composés d'exendine-4 acylée
EP2615108B1 (fr)	2006-09-08	2016-10-26	Ambrx, Inc.	Polypeptide plasmatique humain modifié ou échafaudages fc et leur utilisations
US8617531B2 (en)	2006-12-14	2013-12-31	Bolder Biotechnology, Inc.	Methods of making proteins and peptides containing a single free cysteine
ES2628063T3 (es)	2007-01-05	2017-08-01	Indiana University Research And Technology Corporation	Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
CA2677932A1 (fr)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Co-agonistes des recepteurs du glucagon/glp-1
WO2008152403A1 (fr)	2007-06-15	2008-12-18	Zealand Pharma A/S	Analogues du glucagon
CN101842386A (zh)	2007-09-05	2010-09-22	诺沃-诺迪斯克有限公司	截短的glp-1衍生物和它们的治疗用途
EP2190872B1 (fr)	2007-09-05	2018-03-14	Novo Nordisk A/S	Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
US20100256056A1 (en)	2007-09-07	2010-10-07	Zheng Xin Dong	Analogues of exendin-4 and exendin-3
EP2036923A1 (fr)	2007-09-11	2009-03-18	Novo Nordisk A/S	Dérivés d'amyline améliorés
EP2036539A1 (fr)	2007-09-11	2009-03-18	Novo Nordisk A/S	Formulations stables d'amyline et ses analogues
WO2009034117A1 (fr)	2007-09-11	2009-03-19	Novo Nordisk A/S	Mélange comprenant de l'amyline, qui est un peptide, et une insuline retard
US8980830B2 (en) *	2007-10-30	2015-03-17	Indiana University Research And Technology Corporation	Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009058662A2 (fr)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Antagonistes du glucagon
EP2214700A4 (fr)	2007-11-02	2012-08-22	Janssen Biotech Inc	Produits d'assemblage semi-synthétiques obtenus par fusion de peptide glp-1/fc, procédés et utilisations
CA2713348C (fr) *	2008-01-30	2018-10-09	Indiana University Research And Technology Corporation	Promedicaments peptidiques a base d'esters
BRPI0906643A2 (pt)	2008-02-01	2019-09-10	Ascendis Pharma As	profármaco compreendendo um conjugado fármaco-ligante
MX2010013454A (es)	2008-06-17	2011-01-21	Tion Indiana University Res And Technology Corpora	Co-agonistas de receptor de glucagon/glp-1.
US8450270B2 (en) *	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
HUE028072T2 (en)	2008-06-17	2016-11-28	Univ Indiana Res & Tech Corp	GIP-based agonists for the treatment of metabolic disease and obesity
RU2578591C2 (ru)	2008-12-19	2016-03-27	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Лекарственные средства, связанные с дипептидами
KR20110110174A (ko)	2008-12-19	2011-10-06	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
WO2010096052A1 (fr)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Analogues d'oxyntomoduline
AU2010215858A1 (en)	2009-02-20	2011-09-22	Cdg Thereapeutics, Inc.	Compositions and methods to prevent and/or treat cancer with Pa -CARD
IN2012DN00377A (fr)	2009-06-16	2015-08-21	Univ Indiana Res & Tech Corp
WO2011075393A2 (fr)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Co-agonistes du récepteur du glucagon/glp-i
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JP2013518115A (ja)	2010-01-27	2013-05-20	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーション	代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
AR080592A1 (es)	2010-03-26	2012-04-18	Lilly Co Eli	Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
ES2661228T3 (es)	2010-05-13	2018-03-28	Indiana University Research And Technology Corporation	Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
KR20130102470A (ko)	2010-06-24	2013-09-17	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
WO2011163473A1 (fr)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique

2006
- 2006-11-06 CN CN200680050578.1A patent/CN101534846B/zh not_active Expired - Fee Related
- 2006-11-06 CA CA2628241A patent/CA2628241C/fr not_active Expired - Fee Related
- 2006-11-06 US US12/092,802 patent/US8338368B2/en not_active Expired - Fee Related
- 2006-11-06 ES ES12163977.7T patent/ES2572952T3/es active Active
- 2006-11-06 WO PCT/US2006/043334 patent/WO2007056362A2/fr active Application Filing
- 2006-11-06 CA CA2913805A patent/CA2913805A1/fr not_active Abandoned
- 2006-11-06 ES ES06827600.5T patent/ES2507098T3/es active Active
- 2006-11-06 EP EP06827600.5A patent/EP1959986B1/fr not_active Not-in-force
- 2006-11-06 EP EP12163977.7A patent/EP2570133B1/fr not_active Not-in-force
2009
- 2009-02-24 HK HK09101716.2A patent/HK1121688A1/xx not_active IP Right Cessation
2012
- 2012-01-24 US US13/357,170 patent/US9018164B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101534846A (zh)	2009-09-16
CA2628241A1 (fr)	2007-05-18
ES2572952T3 (es)	2016-06-03
CA2913805A1 (fr)	2007-05-18
EP1959986B1 (fr)	2014-07-23
US20090137456A1 (en)	2009-05-28
US20120196804A1 (en)	2012-08-02
ES2507098T3 (es)	2014-10-14
CN101534846B (zh)	2014-11-05
EP2570133B1 (fr)	2016-03-23
US8338368B2 (en)	2012-12-25
WO2007056362A3 (fr)	2009-04-23
US9018164B2 (en)	2015-04-28
EP1959986A4 (fr)	2010-02-10
EP1959986A2 (fr)	2008-08-27
EP2570133A1 (fr)	2013-03-20
WO2007056362A2 (fr)	2007-05-18
CA2628241C (fr)	2016-02-02

Publication	Publication Date	Title
HK1121688A1 (en)	2009-04-30	Glucagon analogs exhibiting physiological solubility and stability
AP2006003768A0 (en)	2006-10-31	TetraazabenzoÄeÜazulene derivatives and analogs tehereof
IL209287A0 (en)	2011-01-31	Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
HK1187499A1 (zh)	2014-04-11	包含二十二碳六烯酸和葉黃素的嬰兒配方
IL177566A0 (en)	2006-12-10	Pharmaceutical formulations
IL181265A0 (en)	2007-07-04	Stabilizing formulations
HK1106687A1 (en)	2008-03-20	Medical camera
IL191907A0 (en)	2008-12-29	Azepinoindole derivatives as pharmaceutical agents
GB0426301D0 (en)	2004-12-29	Pharmaceutical formulations
IL190953A0 (en)	2009-09-22	Cyclopropylacetic acid derivatives and use thereof
EP1773871A4 (fr)	2008-07-16	Composés associés au facteur de différenciation tissulaire et leurs analogues
SI2497780T1 (sl)	2015-08-31	Spojine, povezane s TDF, in njihovi analogi
HK1092711A1 (en)	2007-02-16	Pharmeceutical composition with improved solubility and fluidity
GB0416397D0 (en)	2004-08-25	Pharmaceutical formulations
GB0423800D0 (en)	2004-12-01	New pharmaceutical formulations
EP1773157A4 (fr)	2013-01-30	Ameliorations apportees a un rayonnage
GB0406048D0 (en)	2004-04-21	Drug formulations
GB0415195D0 (en)	2004-08-11	Syringe
DE602005002728D1 (de)	2007-11-15	Coffein enthaltendes Konfekt
IL182792A0 (en)	2007-08-19	Pharmaceutical compositions containing gepirone
GB2428195B (en)	2009-04-15	Patient stability aid
GB2406659B (en)	2006-11-29	Medical clock
GB0401762D0 (en)	2004-03-03	Showcase
IL183708A0 (en)	2007-09-20	New carbamazepine formulations having improved solubility
GB0521953D0 (en)	2005-12-07	Double-ended sex toy

Legal Events

Date	Code	Title	Description
2018-06-01	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20171106